New ultrasound technique could eliminate need for contrast dye in pancreatic cyst exams
NCT ID NCT07663734
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study investigates whether a new ultrasound technology called Superb Microvascular Imaging (SMI) can accurately analyze material inside pancreatic cysts (PIMPTs) without using a contrast agent. Currently, doctors inject a contrast dye during endoscopic ultrasound to assess cancer risk. SMI may provide similar information without the injection. The trial will enroll 60 patients with pancreatic cysts and compare SMI results to standard contrast-enhanced imaging.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Superb Microvascular Imaging (SMI) ultrasound
- What this could lead to
- If successful, SMI could replace contrast injections for evaluating pancreatic cysts, making the procedure faster and safer.
- What could go wrong
- This is an early exploratory study with no prior data on SMI for this use. The technique may not be accurate enough to replace current methods.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAPILLARY AND MUCINOUS INTRADUCTAL TUMOURS OF THE PANCREAS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Privé Jean Mermoz
Lyon, 69008, France